ClinicalTrials.gg
Status unknownNCT05654090Updated Feb 1, 2023

Evaluate Bioequivalence of Burotam (1/1 g/Vial)

A Phase 4 interventional study of cefoperazone sodium and sulbactam sodium in Infectious Diseases, sponsored by Yung Shin Pharm. Ind. Co., Ltd.. Status unknown at 1 site in Taiwan. Open to participants aged 20 Years to 20 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-02-01.

Sponsored by Yung Shin Pharm. Ind. Co., Ltd. · Phase 4, Interventional, and Other

The sponsor has not verified this record recently (last verified Aug 2022), so the status shown — last known as Active, not recruiting — may be out of date.

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Aug 2022, registered Dec 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
20 Years to 20 Years
01

Study summary

A randomized, single-dose, two-way crossover study to evaluate bioequivalence of two formulations of cefoperazone sodium and sulbactam sodium combination (1/1 g/vial) after intravenous infusion of 1 g cefoperazone sodium and 1 g sulbactam sodium in healthy volunteers under fasting conditions

02

Conditions studied

  • Infectious Diseases

Browse trials for

03

In context

Communicable Diseases

627 studies on the registry are indexed under Communicable Diseases; 128 are open to participants now.

This study's planned enrollment of 14 is below the median of 89 across 380 interventional studies indexed under Communicable Diseases.

Browse Communicable Diseases studies →

Lead sponsor

Yung Shin Pharm. Ind. Co., Ltd. is the lead sponsor of 19 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 20 Years
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy adult male or female subjects between 20-45 years of age (inclusive) at the screening visit.
  2. (BMI) between 18 and 27 kg/m2 (not inclusive) at the screening visit.
  3. Acceptable medical history and physical examination including:

    • no particular abnormalities in results within six months prior to Period I dosing.
    • no particular clinical significance in general disease history within two months prior to Period I dosing.
  4. Acceptable biochemistry determinations (within normal limits or considered by the investigator or physician to be of no clinical significance) within two months prior to Period I dosing, which includes (SGOT), ALT (SGPT), γ-GT, alkaline phosphatase, total , albumin, glucose, BUN, uric acid, creatinine, total cholesterol and triglyceride (TG).
  5. Acceptable hematology (within normal limits or considered by the investigator or physician to be of no clinical significance) within two months prior to Period I dosing, which includes , hematocrit, red blood cell count, white blood cell count with differentials and .
  6. Acceptable urinalysis (within normal limits or considered by the investigator or physician to be of no clinical significance) within two months prior to Period I dosing, which includes pH, blood, glucose, ketones, bilirubin and protein.
  7. Female of practicing an acceptable method of for the duration of the study.
  8. Have signed the written to participate in the study.

Exclusion criteria

Exclusion Criteria:

  1. A disorder involving the cardiovascular, respiratory, hepatic, renal, urinary tract, gastrointestinal, immunologic, hematologic, endocrine or neurologic system(s) or psychiatric disease.
  2. A clinically significant illness or surgery within four weeks prior to Period I dosing.
  3. History of gastrointestinal obstruction, inflammatory bowel disease, gallbladder disease, pancreas disorder over last two years or history of gastrointestinal tract surgery over last five years.
  4. History of kidney disease or urination problem over last two years deemed by the investigator to be clinically significant.
  5. Known or suspected history of drug abuse within lifetime.
  6. History of alcohol addiction or abuse within last five years or use of more than 7 units of alcohol per week within two weeks prior to dosing. (1 unit of alcohol = 10 g of alcohol or about 350 mL of beer or about 83 mL of red wine or about 30 mL of beverage containing 40% (v/v) alcohol).
  7. History of allergic response(s) to palonosetron or any other related drugs.
  8. Evidence of chronic or acute infectious diseases.
  9. Positive result for serum surface antigen (HBsAg), antibody (HCVAb), or (HIV).
  10. Female subjects demonstrating a positive pregnancy screen prior to the study.
  11. Female subjects who are currently breastfeeding.
  12. Taking any drug known to induce or inhibit hepatic drug metabolism within four weeks prior to Period I dosing. Examples of inducers include: piperidines, carbamazepine, dexamethasone and rifampin. Examples of inhibitors include: cimetidine, diphenhydramine, fluvastatin, methadone and ranitidine.
  13. Taking any prescription medications within four weeks or any nonprescription medications (excluding flu vaccination) within two weeks prior to Period I dosing.
  14. Use of any drug within four weeks prior to Period I dosing.
  15. Use of any COVID-19 vaccine within seven days prior to Period I dosing.
  16. Donating more than 250 mL of blood within two months prior to Period I dosing or donating plasma (e.g. plasmapheresis) within two weeks prior to Period I dosing.
  17. Any other medical reason as determined by the investigator.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
14 participants (estimated)

Study arms

  • Experimental
    cefoperazone sodium and sulbactam sodium (Product name:Burotam)

    Single dose Burotam

    Drug: cefoperazone sodium and sulbactam sodium

  • Active comparator
    cefoperazone sodium and sulbactam sodium (Product name:Brosym)

    Single dose Brosym

    Drug: cefoperazone sodium and sulbactam sodium

Interventions

  • Drugcefoperazone sodium and sulbactam sodium

    Drug page: Sulbactam

    Pharmacokinetic study under fasting conditions

06

What researchers measure

Primary outcomes

  1. Peak plasma concentration (Cmax)

    Time frame: 0 (pre-dose), 5, 10 minutes after the start of infusion, immediately after the end of infusion (15 minutes after the start of infusion), and 5, 15, 30, and 45 minutes, and 1.75, 2.75, 3.75, 4.75, 5.75, 7.75, and 11.75 hours after the end of infusion

  2. Area under the concentration-time curve from time zero to time of last quantifiable

    Time frame: 0 (pre-dose), 5, 10 minutes after the start of infusion, immediately after the end of infusion (15 minutes after the start of infusion), and 5, 15, 30, and 45 minutes, and 1.75, 2.75, 3.75, 4.75, 5.75, 7.75, and 11.75 hours after the end of infusion

  3. Area under the concentration-time curve from time zero to infinity (AUC 0-∞)

    Time frame: 0 (pre-dose), 5, 10 minutes after the start of infusion, immediately after the end of infusion (15 minutes after the start of infusion), and 5, 15, 30, and 45 minutes, and 1.75, 2.75, 3.75, 4.75, 5.75, 7.75, and 11.75 hours after the end of infusion

07

Study locations

1 site
  • Taichung Veterans General Hospital
    Taichung, Taiwan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Nov 2022, 2 months.

Of 13 phase 4 interventional studies under Communicable Diseases, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 65. This study's 2 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2022
First posted
Dec 16, 2022
StartActual
Aug 25, 2022
Primary completionActual
Nov 18, 2022
CompletionEst.
Feb 20, 2023
Last update
Feb 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05654090
Lead sponsor
Yung Shin Pharm. Ind. Co., Ltd.
Responsible party
Sponsor
First posted
Dec 16, 2022
Start date
Aug 25, 2022
Primary completion
Nov 18, 2022
Completion
Feb 20, 2023 (estimated)
Last update
Feb 1, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sulbactam

Start the discussion